Loading...
XSHG603520
Market cap543mUSD
Dec 24, Last price  
9.01CNY
Name

Zhejiang Starry Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603520 chart
P/E
89.30
P/S
1.80
EPS
0.10
Div Yield, %
1.73%
Shrs. gr., 5y
0.74%
Rev. gr., 5y
19.78%
Revenues
2.20b
+3.04%
506,582,117574,710,788685,904,772658,482,615695,660,000672,945,253710,939,018890,470,7811,308,841,6351,367,087,2411,999,916,8882,131,239,9882,195,986,154
Net income
44m
67,567,06535,784,63663,657,74467,704,20868,944,11876,121,53983,116,97493,676,375170,331,965238,729,340323,754,754044,232,089
CFO
46m
-41,072,600103,342,43174,993,069144,000,55994,879,3667,679,73418,104,512191,835,586246,768,072174,479,180508,839,385046,126,089
Dividend
Sep 09, 20240.05 CNY/sh
Earnings
May 21, 2025

Profile

Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products comprise levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is based in Xianju, China.
URL
http://www.starrypharm.com
IPO date
Mar 09, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,195,986
3.04%
2,131,240
6.57%
1,999,917
46.29%
Cost of revenue
1,939,744
1,891,012
1,451,941
Unusual Expense (Income)
NOPBT
256,242
240,228
547,976
NOPBT Margin
11.67%
11.27%
27.40%
Operating Taxes
799
6,521
65,624
Tax Rate
0.31%
2.71%
11.98%
NOPAT
255,443
233,707
482,352
Net income
44,232
 
323,755
35.62%
Dividends
(68,251)
(122,438)
(122,435)
Dividend yield
1.42%
1.83%
0.77%
Proceeds from repurchase of equity
(10,183)
BB yield
0.21%
Debt
Debt current
1,855,028
2,106,641
1,161,230
Long-term debt
734,480
676,929
748,117
Deferred revenue
94,410
43,348
Other long-term liabilities
91,665
1
3,857
Net debt
1,894,932
1,986,069
974,052
Cash flow
Cash from operating activities
46,126
508,839
CAPEX
(266,225)
Cash from investing activities
(255,560)
Cash from financing activities
83,011
363,584
FCF
252,969
(529,464)
372,439
Balance
Cash
565,157
662,440
845,898
Long term investments
129,418
135,061
89,396
Excess cash
584,776
690,939
835,299
Stockholders' equity
806,055
994,327
1,118,394
Invested Capital
3,855,281
3,948,958
3,291,739
ROIC
6.55%
6.46%
17.96%
ROCE
5.77%
5.18%
13.27%
EV
Common stock shares outstanding
340,247
342,252
341,943
Price
14.08
-28.05%
19.57
-57.85%
46.43
-1.25%
Market cap
4,790,676
-28.47%
6,697,864
-57.81%
15,876,404
1.03%
EV
6,691,903
8,689,907
16,890,015
EBITDA
435,796
400,670
702,941
EV/EBITDA
15.36
21.69
24.03
Interest
108,653
92,600
73,823
Interest/NOPBT
42.40%
38.55%
13.47%